| Segment Reporting [Table Text Block] |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Sale of Product | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Theranostics Products | | $ | 1,078,127 | | | $ | 1,905,402 | | | $ | 2,475,409 | | | $ | 3,692,456 | |
| Cobalt Products | | | 497,670 | | | | 678,015 | | | | 507,409 | | | | 750,465 | |
| Calibration & Reference Products | | | 1,055,031 | | | | 1,013,814 | | | | 1,937,821 | | | | 2,340,580 | |
| Medical Device Products | | | 40,957 | | | | 58,089 | | | | 130,070 | | | | 110,719 | |
| Fluorine Products | | | — | | | | — | | | | — | | | | — | |
| Total Segments | | | 2,671,785 | | | | 3,655,320 | | | | 5,050,709 | | | | 6,894,220 | |
| Corporate revenue | | | — | | | | — | | | | — | | | | — | |
| Total Consolidated | | $ | 2,671,785 | | | $ | 3,655,320 | | | $ | 5,050,709 | | | $ | 6,894,220 | |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Depreciation and Amortization | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Theranostics Products | | $ | 12,436 | | | $ | 9,895 | | | $ | 24,872 | | | $ | 18,104 | |
| Cobalt Products | | | 18,867 | | | | 16,360 | | | | 35,967 | | | | 32,362 | |
| Calibration & Reference Products | | | 32,868 | | | | 31,480 | | | | 70,606 | | | | 61,360 | |
| Medical Device Products | | | — | | | | — | | | | — | | | | — | |
| Fluorine Products | | | 28,970 | | | | 26,095 | | | | 57,940 | | | | 52,190 | |
| Total Segments | | | 93,141 | | | | 83,830 | | | | 189,385 | | | | 164,016 | |
| Corporate depreciation and amortization | | | 13,945 | | | | 17,207 | | | | 27,888 | | | | 34,966 | |
| Total Consolidated | | $ | 107,086 | | | $ | 101,037 | | | $ | 217,273 | | | $ | 198,982 | |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Segment Income (Loss) | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Theranostics Products | | $ | 172,918 | | | $ | 1,009,387 | | | $ | 579,815 | | | $ | 1,886,381 | |
| Cobalt Products | | | 63,273 | | | | (97,040 | ) | | | (183,530 | ) | | | (245,266 | ) |
| Calibration & Reference Products | | | (98,799 | ) | | | (38,387 | ) | | | (216,451 | ) | | | 229,176 | |
| Medical Device Products | | | (214,080 | ) | | | (201,305 | ) | | | (377,675 | ) | | | (382,974 | ) |
| Fluorine Products | | | (32,809 | ) | | | 3,905 | | | | (44,193 | ) | | | (22,254 | ) |
| Total Segments | | | (109,497 | ) | | | 676,560 | | | | (242,034 | ) | | | 1,465,063 | |
| Corporate loss | | | (772,500 | ) | | | (837,345 | ) | | | (1,988,049 | ) | | | (1,738,542 | ) |
| Net Loss | | $ | (881,997 | ) | | $ | (160,785 | ) | | $ | (2,230,083 | ) | | $ | (273,479 | ) |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Expenditures for Segment Assets | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Theranostics Products | | $ | — | | | $ | 4,046 | | | $ | 49,481 | | | $ | 50,561 | |
| Cobalt Products | | | — | | | | — | | | | 110,023 | | | | 12,835 | |
| Calibration & Reference Products | | | — | | | | 57,449 | | | | — | | | | 75,663 | |
| Medical Device Products | | | — | | | | — | | | | 45,671 | | | | 28,876 | |
| Fluorine Products | | | — | | | | — | | | | — | | | | — | |
| Total Segments | | | — | | | | 61,495 | | | | 205,175 | | | | 167,935 | |
| Corporate purchases | | | — | | | | — | | | | — | | | | 22,439 | |
| Total Consolidated | | $ | — | | | $ | 61,495 | | | $ | 205,175 | | | $ | 190,374 | |
| | | June 30, | | | December 31, | |
| Segment Assets | | 2026 | | | 2025 | |
| Theranostics Products | | $ | 727,561 | | | $ | 1,115,238 | |
| Cobalt Products | | | 216,076 | | | | 260,960 | |
| Calibration & Reference Products | | | 2,964,836 | | | | 2,896,335 | |
| Medical Device Products | | | 922,118 | | | | 697,503 | |
| Fluorine Products | | | 4,741,749 | | | | 4,771,359 | |
| Total Segments | | | 9,572,340 | | | | 9,741,395 | |
| Corporate assets | | | 7,073,833 | | | | 8,095,237 | |
| Total Consolidated | | $ | 16,646,173 | | | $ | 17,836,632 | |
|